BRPI0409302A - derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos - Google Patents

derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos

Info

Publication number
BRPI0409302A
BRPI0409302A BRPI0409302-0A BRPI0409302A BRPI0409302A BR PI0409302 A BRPI0409302 A BR PI0409302A BR PI0409302 A BRPI0409302 A BR PI0409302A BR PI0409302 A BRPI0409302 A BR PI0409302A
Authority
BR
Brazil
Prior art keywords
muscarinic receptor
preparation
pharmaceutical composition
composition containing
receptor antagonists
Prior art date
Application number
BRPI0409302-0A
Other languages
English (en)
Inventor
Mohammad Salman
Pakala Kumara Savithru Sarma
Sankaranarayanan Dharmarajan
Anita Chugh
Naresh Kumar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2003/001367 external-priority patent/WO2004005252A1/en
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BRPI0409302A publication Critical patent/BRPI0409302A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

"DERIVADOS AZABICICLO COMO ANTAGONISTAS DE RECEPTORES MUSCARìNICOS, MéTODO PARA SUA PREPARAçãO E COMPOSIçãO FARMACêUTICA CONTENDO OS MESMOS". A presente invenção refere-se a antagonistas de receptores muscarínicos de Fórmula (I) que são úteis, entre outros usos, para o tratamento de várias doenças dos sistemas respiratório, urinário e gastrointestinal mediados através de receptores muscarínicos. Especificamente, a invenção refere-se a derivados de compostos azabicíclicos que incluem, por exemplo, 6-substituído azabiciclo ¢3.1.0! hexanos, bem como composições farmacêuticas contendo tais compostos e métodos de tratamento de doenças mediadas por receptores muscarínicos.
BRPI0409302-0A 2003-04-11 2004-01-06 derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos BRPI0409302A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2003/001367 WO2004005252A1 (en) 2002-07-08 2003-04-11 Azabicyclo derivatives as muscarinic receptor antagonists
PCT/IB2004/000008 WO2004089900A1 (en) 2003-04-11 2004-01-06 Azabicyclo derivatives as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0409302A true BRPI0409302A (pt) 2006-04-11

Family

ID=33156169

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0409302-0A BRPI0409302A (pt) 2003-04-11 2004-01-06 derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
BRPI0409308-9A BRPI0409308A (pt) 2003-04-11 2004-01-07 derivados azabiciclo como antagonistas de receptores muscarìnicos, composição farmacêutica e processo para sua preparação

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0409308-9A BRPI0409308A (pt) 2003-04-11 2004-01-07 derivados azabiciclo como antagonistas de receptores muscarìnicos, composição farmacêutica e processo para sua preparação

Country Status (10)

Country Link
US (2) US20070021487A1 (pt)
EP (2) EP1626957A1 (pt)
JP (2) JP2006522787A (pt)
CN (2) CN100436414C (pt)
AU (2) AU2004228452A1 (pt)
BR (2) BRPI0409302A (pt)
CA (2) CA2522071A1 (pt)
EA (1) EA009387B1 (pt)
NZ (2) NZ542952A (pt)
WO (2) WO2004089900A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ537584A (en) 2002-07-08 2006-07-28 Ranbaxy Lab Ltd 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
ES2634841T3 (es) * 2003-10-14 2017-09-29 Pfizer Products Inc. Derivados bicíclicos [3.1.0] como inhibidores del transportador de glicina
WO2006064304A1 (en) * 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
EP1888525A1 (en) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists
WO2007007282A2 (en) * 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
WO2007039884A1 (en) 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited 3 -azabicyclooctane derivatives as muscarinic receptor antagonists
WO2007045979A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
US20100222393A1 (en) * 2005-12-30 2010-09-02 Naresh Kumar Muscarinic receptor antagonists
WO2007110782A1 (en) 2005-12-30 2007-10-04 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2008029349A2 (en) * 2006-09-04 2008-03-13 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
CN103772379B (zh) * 2014-01-26 2016-06-15 寿光富康制药有限公司 一种曲司氯铵关键中间体的制备方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490714A (en) * 1947-05-13 1949-12-06 Du Pont Preparation of diazoacetic esters
NL267508A (pt) * 1960-07-26
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5001160A (en) * 1988-04-28 1991-03-19 Marion Laboratories, Inc. 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5164402A (en) * 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
RU2049777C1 (ru) 1989-08-16 1995-12-10 Пфайзер Инк. Азабицикло-хинолон-карбоновые кислоты или их фармацевтически приемлемые кислотно-аддитивные соли и промежуточные продукты для их получения
GB8928042D0 (en) 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
US5281601A (en) * 1989-12-12 1994-01-25 Pfizer Inc. Muscarinic receptor antagonists
FR2659323B1 (fr) 1990-03-07 1992-06-12 Synthelabo Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique.
GB9020051D0 (en) * 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
FI100051B (fi) 1992-02-18 1997-09-15 Favorit Oy Kompostori
JP3429338B2 (ja) 1992-07-27 2003-07-22 杏林製薬株式会社 新規なアリールグリシンアミド誘導体及びその製造法
JPH06135958A (ja) 1992-10-28 1994-05-17 Tanabe Seiyaku Co Ltd ベンゾシクロヘプテン誘導体及びその製法
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
DE59306269D1 (de) 1993-02-24 1997-05-28 Siemens Ag Sperrwandler-Schaltnetzteil mit einem Halbleiterschaltelement geringer Spannungsfestigkeit
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
EP0823423B1 (en) * 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
CA2179574A1 (en) * 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
DE69615214T2 (de) * 1995-10-13 2002-06-27 Banyu Pharmaceutical Co., Ltd. Substituierte heteroaromatische derivate
WO1997045414A1 (en) 1996-05-31 1997-12-04 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
EP0843141B1 (de) * 1996-11-19 1998-06-03 GEA Wärme- und Umwelttechnik GmbH Kohlenaufgabeeinrichtung für eine Braunkohlentrocknungsanlage
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
EP1001764A4 (en) 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
US6319920B1 (en) 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
MXPA02005596A (es) 1999-12-07 2004-09-10 Theravance Inc Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
SE9904765D0 (sv) 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
EP1289965B1 (en) 2000-05-25 2005-10-26 F. Hoffmann-La Roche Ag Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
HUP0302015A2 (hu) 2000-05-25 2003-10-28 F. Hoffmann-La Roche Ag. Helyettesített 1-aminoalkil-laktámok és felhasználásuk muszkarin receptor antagonistaként
WO2002006241A1 (en) 2000-06-14 2002-01-24 Muscagen Limited 1, 2, 3, 5 -tetrahydrobenzo`c!azepin-4-one derivatives having muscarinic antagonist activity
AU6610001A (en) 2000-06-27 2002-01-08 S A L V A T Lab Sa Carbamates derived from arylalkylamines
CA2415468A1 (en) * 2000-07-11 2003-01-10 Yoshio Ogino Ester derivatives
HUP0303529A3 (en) 2000-12-22 2008-03-28 Almirall Ag New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
CN1250545C (zh) * 2000-12-28 2006-04-12 阿尔米雷尔普罗迪斯制药有限公司 新的奎宁环衍生物类及含有这类衍生物的药物组合物
WO2002083863A2 (en) 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
RU2004110717A (ru) 2001-10-17 2005-10-20 Юсиби, С.А. (Be) Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов
PL370765A1 (en) 2001-12-03 2005-05-30 F.Hoffmann-La Roche Ag 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
EP1453806B1 (en) 2001-12-03 2007-12-19 F. Hoffmann-La Roche Ag Aminotetralin derivatives as muscarinic receptor antagonist
NZ537584A (en) * 2002-07-08 2006-07-28 Ranbaxy Lab Ltd 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
WO2004014853A1 (en) 2002-07-31 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
AU2002321711A1 (en) 2002-08-09 2004-02-25 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives useful as muscarinic receptor antagonist
JP2006501236A (ja) * 2002-08-23 2006-01-12 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有３，６−二置換アザビシクロ（３．１．０）ヘキサン誘導体
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
AU2002347553A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
AU2002356369A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Xanthine derivatives as muscarinic receptor antagonists
AU2002347552A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004069835A1 (en) 2003-02-07 2004-08-19 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003223010A1 (en) 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CA2521788A1 (en) 2003-04-10 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
FR2855805B1 (fr) 2003-06-06 2005-08-05 Vallourec Vitry Element de structure pour vehicule, capable d'un meilleur comportement aux chocs
EP1746998A1 (en) 2004-03-22 2007-01-31 Ranbaxy Laboratories, Ltd. Combination therapy for lower urinary tract symptoms
EP1796667A2 (en) 2004-09-27 2007-06-20 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2006064304A1 (en) 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists

Also Published As

Publication number Publication date
JP2006522787A (ja) 2006-10-05
BRPI0409308A (pt) 2006-05-02
EP1620087A1 (en) 2006-02-01
AU2004228452A1 (en) 2004-10-21
AU2004228760A1 (en) 2004-10-21
WO2004089900A1 (en) 2004-10-21
CA2522071A1 (en) 2004-10-21
AU2004228452A2 (en) 2004-10-21
EA200501593A1 (ru) 2006-06-30
CN1795176A (zh) 2006-06-28
NZ542951A (en) 2008-11-28
CN1794985A (zh) 2006-06-28
US20070021487A1 (en) 2007-01-25
EA009387B1 (ru) 2007-12-28
EP1626957A1 (en) 2006-02-22
CN100436414C (zh) 2008-11-26
CA2521989A1 (en) 2004-10-21
US20060287380A1 (en) 2006-12-21
NZ542952A (en) 2008-11-28
WO2004089364A1 (en) 2004-10-21
JP2006522788A (ja) 2006-10-05
US7446123B2 (en) 2008-11-04

Similar Documents

Publication Publication Date Title
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
BRPI0417323A (pt) indóis, 1h-indazóis, 1,2-benzisoxazóis, e 1,2-benzisotiazóis, composto, composição farmacêutica e usos dos mesmos
BR0207526A (pt) Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
BRPI0708490B8 (pt) composto, composição farmacêutica, processo para preparar um composto da fórmula (i), e uso de um composto
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
BRPI0508461B8 (pt) diaminopirimidinas, seus usos, e composição farmacêutica
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
BRPI0809998B8 (pt) composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
BRPI0409308A (pt) derivados azabiciclo como antagonistas de receptores muscarìnicos, composição farmacêutica e processo para sua preparação
BRPI0415769A (pt) alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as
BRPI0409436A (pt) compostos de 4-fenil-piperidina e a sua utilização como moduladores de receptores de opióides
BRPI0411585A (pt) compostos, composição farmacêutica e método de aglutinar receptores opióides em um paciente com necessidade dos mesmos
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
DE60225195D1 (de) Flavaxat-derivate als muscarin-rezeptor antagonisten
UY29212A1 (es) Azabenzoxazoles para el tratamiento de trastornos del snc
MX2009005541A (es) Indoles que actuan como antagonistas del receptor v1a.
WO2006035282A3 (en) Muscarinic receptor antagonists
BR0112130A (pt) Composições farmacêuticas e métodos para uso
WO2006018708A3 (en) Pyrrolidine derivatives as muscarinic receptor antagonists
DE602004018844D1 (de) Als antagonisten des muscarinrezeptors geeignete xanthinderivate
BRPI0417936A (pt) composto, um seu sal farmaceuticamente aceitável, diastereÈmeros, enanciÈmeros, ou misturas destes, uso de um composto, composição farmacêutica, métodos para a terapia de dor e de distúrbios gastrintestinais em um animal de sangue quente, e, processo para preparar um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2174 DE 04/09/2012.